Therapeutic novel strategy targeting ELOVL6 to induce KRAS G12V protein degradation

I. Introduction

KRAS gene mutations have long been an unsolved challenge in cancer treatment, with the KRAS G12V mutation frequently occurring in pancreatic cancer (~35%) and colorectal cancer (~30%). Unlike KRAS G12C, the G12V mutation lacks a cysteine residue available for covalent binding, making it historically difficult to develop direct-targeting inhibitors. A recent study published in Nature Chemical Biology used genome-wide CRISPR screening to identify fatty acid elongase ELOVL6 as a synthetic lethal target for KRAS G12V. Inhibiting ELOVL6 induces KRAS G12V protein detachment from the cell membrane and degradation via the lysosomal pathway, demonstrating significant anti-tumor effects in preclinical models and providing a novel strategy for treating KRAS G12V-mutant tumors.

II. Research Background and Design

The KRAS protein, a critical node in intracellular signal transduction, alternates between inactive and active states by binding GDP and GTP under physiological conditions. Mutant KRAS, due to impaired GTP hydrolysis, remains persistently activated, abnormally driving downstream proliferative signals. KRAS G12V lacks reactive amino acid residues for covalent targeting, rendering traditional direct inhibition strategies ineffective.

The research team shifted focus to identify gene targets that could indirectly clear KRAS G12V protein. Using CRISPR-Cas9 technology, they conducted a genome-wide screen in KRAS G12V homozygous mutant colorectal cancer cells (SW480) and KRAS wild-type cells (HT29). Magnetic sorting was employed to enrich cell populations with reduced KRAS protein levels. By comparing the effects of gene knockout on KRAS protein levels between the two cell types, key genes selectively regulating KRAS G12V stability were identified. The screening results showed that ELOVL6 knockout significantly reduced KRAS protein levels in mutant cells but had no apparent effect in wild-type cells, making it the top candidate target.

III. Molecular Mechanism of ELOVL6 in Regulating KRAS G12V Membrane Localization

ELOVL6 is a long-chain fatty acid elongase that catalyzes the elongation of palmitic acid to stearic acid and oleic acid, which are important precursors for cell membrane phospholipid synthesis. Phosphatidylserine (PS), a key phospholipid component of cell membranes, has its acyl chain composition influencing the anchoring stability of membrane proteins.

Lipidomics analysis revealed that ELOVL6 knockout or inhibitor treatment led to decreased intracellular levels of stearic acid and oleic acid, thereby affecting the synthesis of specific molecular forms of phosphatidylserine, particularly the subtype with mixed 16:0/18:1 acyl chains. KRAS G12V protein is highly dependent on this specific phosphatidylserine composition. When mixed-chain phosphatidylserine is reduced, KRAS G12V loses its membrane anchoring site, detaches from the cell membrane, and enters the lysosomal degradation pathway. In contrast, wild-type KRAS protein has lower requirements for phosphatidylserine acyl chain composition and can maintain membrane localization by binding to other subtypes, enabling selective degradation of mutant protein without affecting normal function.

Validation in cell models showed that ELOVL6 knockout reduced KRAS G12V protein levels by 65% in SW480 cells, while wild-type KRAS in HT29 cells remained unchanged. In KRAS G12V heterozygous mutant lung cancer cells (NCI-H441), ELOVL6 knockout also reduced mutant protein levels by 50%. ELOVL6 inhibitor treatment concentration-dependently decreased KRAS G12V protein levels, accompanied by reduced ERK phosphorylation and inhibited cell proliferation. Exogenous supplementation of mixed-chain phosphatidylserine reversed these effects, further confirming the central role of phosphatidylserine composition changes in KRAS G12V degradation.

IV. Anti-Tumor Effects of ELOVL6 Inhibitors In Vivo

In a KRAS G12V mutant colorectal cancer SW403 cell-derived xenograft model, daily oral administration of an ELOVL6 inhibitor for 35 days reduced tumor volume by approximately 60% in the high-dose group compared to controls, with mouse survival rates increasing from 30% to 70%. Immunohistochemical analysis of tumor tissues showed reduced KRAS protein expression, along with significant decreases in phosphorylated ERK and proliferation marker Ki67-positive cell proportions, confirming the correlation between target inhibition and signaling pathway inactivation.

The therapeutic efficacy of this strategy was validated in multiple KRAS mutant models. In KRAS G12V mutant lung cancer (NCI-H441) and pancreatic cancer (CFPAC-1) models, ELOVL6 inhibitors also significantly suppressed tumor growth. Notably, CFPAC-1 carries a KRAS G12D mutation, suggesting that the ELOVL6-dependent membrane anchoring mechanism may apply to multiple KRAS mutant subtypes, potentially offering broad therapeutic value for KRAS mutations.

V. Application of KRAS G12V & CRBN Binding Kit in Degradation Mechanism Studies

In studying the mechanism of ELOVL6 inhibitor-induced KRAS G12V degradation, accurately assessing mutant protein stability and degradation pathways is crucial. The Human KRAS G12V & CRBN Binding Kit (GDP load) provides a standardized detection tool for studying interactions between KRAS G12V and E3 ubiquitin ligases. Based on the conformational characteristics of KRAS G12V protein in its GDP-bound state, the kit simulates the process by which protein degraders or endogenous degradation pathways recruit target proteins to CRBN ligase. Using time-resolved fluorescence resonance energy transfer (TR-FRET) technology, it quantitatively detects KRAS G12V binding activity to CRBN, enabling evaluation of whether candidate compounds induce KRAS degradation via the ubiquitin-proteasome pathway. In this study, the kit could be used to verify whether KRAS G12V undergoes ubiquitination and recruitment to the CRBN pathway after ELOVL6 inhibitor treatment or to screen for KRAS G12V-targeting PROTAC molecules with direct degradation functions.

VI. Summary and Outlook

This study is the first to identify ELOVL6 as a synthetic lethal target for KRAS G12V, selectively inducing mutant protein detachment from the membrane and lysosomal degradation by regulating the acyl chain composition of cell membrane phosphatidylserine. This mechanism differs entirely from the "occupancy-driven" strategy of traditional KRAS G12C inhibitors, offering a novel therapeutic approach for KRAS mutant subtypes lacking covalent binding sites. In preclinical models, ELOVL6 inhibitors demonstrated significant tumor suppression as monotherapy and were effective against multiple KRAS mutation types, potentially overcoming current limitations in KRAS-targeted therapy.